Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hutchison MediPharma has commenced an open-label, dose-escalation Fruquintinib Phase I trial following approval from the State Food and Drug Administration (SFDA) in China.
Subscribe to our email newsletter
Pre-clinical data shows that this compound is a potent suppressor of angiogenesis, an established approach in anti-cancer treatment.
The primary objective of the trial is to determine the maximum tolerated dose (MTD) and assess the safety and tolerability in patients with advanced solid tumours.
However, the secondary objectives include the assessment of single and multiple dose pharmacokinetics and the evaluation of Fruquintinib’s antitumor activity.
Hutchison MediPharma CEO Smantha Du said Fruquintinib is highly selective of all three forms of VEGFR, as well as having potent activity against aggressive tumours.
"Starting the Phase I trials takes an additional step toward our goal of developing more effective and safe anti-cancer agents for patients globally," Du said.